Jortan Pharmaceuticals Inc. (JORTAN) was founded around aspartic protease inhibitors as potential diabetes therapeutics based on technology from the Oklahoma Medical Research Foundation (OMRF). JORTAN focuses initially on BACE-2 (Memapsin 1) inhibitors as a novel approach to the treatment of diabetes.
JORTAN has partnered with Accele BioPharma, Inc., a biotechnology accelerator. Accele Venture Partners has provided seed capital to JORTAN to fund initial development milestones. JORTAN is supported by strong intellectual property, has shown early success in validated preclinical models, and has significant commercial potential in the field of Type 1 and Type 2 diabetes. Accele BioPharma is interested in discussing this program and related intellectual property with investors and relevant commercialization partners.